{"name":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","slug":"grupo-espa-ol-de-linfomas-y-transplante-aut-logo-de-m-dula-sea","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Bendamustine-EAM","genericName":"Bendamustine-EAM","slug":"bendamustine-eam","indication":"Conditioning regimen prior to autologous hematopoietic stem cell transplantation in lymphomas and other hematologic malignancies","status":"phase_2"},{"name":"Consolidation with Brentuximab Vedotin","genericName":"Consolidation with Brentuximab Vedotin","slug":"consolidation-with-brentuximab-vedotin","indication":"Hodgkin lymphoma","status":"phase_2"},{"name":"Induction without Brentuximab Vedotin","genericName":"Induction without Brentuximab Vedotin","slug":"induction-without-brentuximab-vedotin","indication":"Lymphoma","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Soludomerin","genericName":"Soludomerin","slug":"soludomerin","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Bendamustine-EAM","genericName":"Bendamustine-EAM","slug":"bendamustine-eam","phase":"phase_2","mechanism":"Bendamustine is an alkylating agent that cross-links DNA to kill rapidly dividing cancer cells, often used in combination with other chemotherapy agents (EAM regimen includes etoposide and cytarabine).","indications":["Conditioning regimen prior to autologous hematopoietic stem cell transplantation in lymphomas and other hematologic malignancies"],"catalyst":""},{"name":"Consolidation with Brentuximab Vedotin","genericName":"Consolidation with Brentuximab Vedotin","slug":"consolidation-with-brentuximab-vedotin","phase":"phase_2","mechanism":"Antibody-drug conjugate targeting CD30","indications":["Hodgkin lymphoma","Systemic anaplastic large cell lymphoma"],"catalyst":""},{"name":"Induction without Brentuximab Vedotin","genericName":"Induction without Brentuximab Vedotin","slug":"induction-without-brentuximab-vedotin","phase":"phase_2","mechanism":"This drug induces a response in lymphoma patients without Brentuximab Vedotin.","indications":["Lymphoma"],"catalyst":""},{"name":"Soludomerin","genericName":"Soludomerin","slug":"soludomerin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":3,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}